

Volume 24 · Number 1 · 2017

Breast Cancer

The Japanese Breast Cancer Society



 Springer

www.springer.com/12282

Breast Cancer誌の現状と Impact Factorについて

The Japanese Breast Cancer Society
14 July 2017

 Springer

Contents

1. Editorial Development

- New Submission / Acceptance Rate

2. Production

- Production Volume / Published Articles

3. Usage

- Top 10 Article Downloads

4. Impact

- Impact Factor / Highly Cited Articles

1 Editorial Development

1.0

1 Editorial Development

1.1 Editorial Status Summary

Submissions	2012	2013	2014	2015	2016	2017
Total Submitted	297	256	280	329	368	202
Total Decided *	289	261	272	315	349	210
Accept	103	75	67	82	76	37
Reject	182	186	198	222	271	173
Acceptance Rate	35.6%	28.7%	24.6%	26.0%	21.8%	17.6%
Average Days to Accept **	104.8	113.1	98.6	94.5	106.5	101.8
Average Days to Reject	35.0	37.8	34.3	29.1	30.4	29.4
Average Days to First Decision	29.1	30.8	30.9	25.9	28.2	26.9

Disclaimer:


* Only the papers for which the 'Final Decision' has been set are taken into account.

** Including days with author.

1 Editorial Development

1.2 New Submissions by Article Type

Article type	2012	2013	2014	2015	2016	2017
Special Feature	9	4	10	11	7	3
Special Article	0	0	0	4	0	0
Conference Paper	2	0	0	0	0	0
Review Article	13	13	18	25	30	26
Original Article	183	179	194	235	279	146
Case Report	82	52	49	47	43	19
Rapid Communication	2	1	5	5	5	3
Editorial	2	2	1	1	2	0
Letters to the Editor	4	5	3	1	2	5
Total	297	256	280	329	368	202




(Source: Editorial Manager, as of 30 Jun 2017)

1 Editorial Development

1.3 Accepted Articles by Article Type

Article type	2012	2013	2014	2015	2016	2017
Special Feature	7	7	8	12	7	4
Special Article	0	0	0	4	0	0
Conference Paper	1	1	0	0	0	0
Review Article	8	4	4	6	8	3
Original Article	74	56	51	56	57	24
Case Report	9	3	0	2	2	1
Rapid Communication	1	1	2	0	1	0
Editorial	1	0	1	1	1	0
Letters to the Editor	2	3	1	1	0	5
Total	103	75	67	82	76	37




(Source: Editorial Manager, as of 30 Jun 2017)

1 Editorial Development

1.4 Acceptance Rate by Article Type

Article type	2012	2013	2014	2015	2016	2017
Special Feature	100	100	100	100	100	100
Special Article	—	—	—	100	—	—
Conference Paper	100	100	—	—	—	—
Review Article	57.1	36.4	25.0	25.0	26.7	12.5
Original Article	42.3	31.1	26.3	25.6	21.8	15.5
Case Report	10.7	5.6	0	4.2	4.7	5.6
Rapid Communication	50.0	100	50.0	0	20.0	0
Editorial	50.0	0	100	100	50.0	—
Letters to the Editor	50.0	60.0	100	50.0	0	83.3
Total	35.6	28.7	24.6	26.0	21.8	17.6
Total (excl. SF, SA, CP, Ed)	32.5	25.7	21.3	20.6	19.5	16.0

(%)




(Source: Editorial Manager, as of 30 Jun 2017)

1 Editorial Development

1.5 New Submissions by Location

Country / Region	2012	2013	2014	2015	2016	2017
Japan	133	86	89	109	80	37
Asia	58	80	84	94	124	69
Americas	16	17	20	19	34	7
Europe	40	22	43	43	45	26
Middle East	43	42	38	52	68	54
Pacific	1	1	0	1	2	1
Africa	6	8	6	11	15	8
Total	297	256	280	329	368	202




(Source: Editorial Manager, as of 30 Jun 2017)

1 Editorial Development

1.6 Acceptance Rate by Location

Country / Region	2012	2013	2014	2015	2016	2017
Japan	52.1	51.0	51.9	53.8	50.0	47.7
Asia	27.7	14.1	12.9	14.9	13.5	8.7
Americas	11.8	13.3	18.2	11.8	8.8	11.1
Europe	26.3	23.8	17.9	19.0	26.7	7.4
Middle East	13.2	17.5	7.3	1.9	7.9	11.8
Pacific	0	—	100	0	0	50.0
Africa	0	0	0	18.2	7.1	0
Total	35.6	28.7	24.6	26.0	21.8	17.6

(%)



(Source: Editorial Manager, as of 30 Jun 2017)

2 Production

2.0

3 Usage

3.0

3 Usage

3.1 Top 10 Full-Text Article Downloads 2016

Title	Author	Article Type	Year	Vol	Issue	Page	Downloads
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer	Kosuke Kawaguchi	Original Article	2017	24	1	111	814
Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells	Angelika Kaczyńska	Original Article	2017	24	2	271	757
HER2-directed therapy: current treatment options for HER2-positive breast cancer	Shahid Ahmed	Review Article	2015	22	2	101	735
Assessment of pain, acceptance of illness, adjustment to life with cancer and coping strategies in breast cancer patients	Aleksandra Czerw	Original Article	2016	23	4	654	735
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer	Eiichi Shiba	Original Article	2016	23	3	499	703
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?	Shigehira Saji	Special Feature	2016	23	1	1	679
Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer	Shinzaburo Noguchi	Original Article	2016	23	5	771	645
The pharmacological and hormonal therapy of hot flushes in breast cancer survivors	Iwona Wiśniewska	Review Article	2016	23	2	178	568
Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections	Rieko Nishimura	Original Article	2016	23	6	917	567
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2	Shinzaburo Noguchi	Original Article	2014	21	6	703	560

(Source: COUNTER Reporting / Business Warehouse)

4 Impact

4.0

4 Impact

4.1 Impact Factorとは？

自然科学176分野8,600誌以上、社会科学56分野3,100誌以上の Science Citation Index® Expanded 及び Social Sciences Citation Index 収録の雑誌を対象にした評価指標の一つ。


特定の1年間において、ある雑誌に掲載された「平均的な論文」がどの程度頻繁に引用されているかを示す尺度。

注) 「平均的な論文」とは、原著論文、総説等、研究結果をまとめた論文を指す。 Editorial や Letter は除外される。

一般に、その雑誌の関連分野における影響度を表す。

4 Impact

4.2 Impact Factor の計算方法




注1 : 2014年issue掲載論文に2012-2013年時点でオンライン出版されている論文が引用されていれば、分子に数えられる。

注2 : 2014年出版のオンライン論文（issue 未掲載）に2012-2013年issue 掲載論文が引用されても、そのオンライン論文が2014年発行のissue に掲載されない限り、分子には数えられない。

4 Impact

4.3 Impact Factor of *Breast Cancer*

	2010	2011	2012	2013	2014	2015	2016
Impact Factor	1.888	1.363	1.330	1.505	1.585	1.170	1.572
Number of cites to articles published in two years before	124	75	80	75	111	58	174
Number of cites to articles published in a previous year	61	64	53	80	57	128	120
Number of articles published in two years before	47	51	51	49	54	52	107
Number of articles published a previous year	51	51	49	54	52	107	80
Rank among oncology journals	125/184	149/194	160/196	162/202	169/211	191/213	183/217
5-Year Impact Factor	—	—	—	1.401	1.490	1.412	1.561
Self Cites	6%	3%	6%	1%	3%	1%	5%



(Source: Clarivate Analytics, Journal Citation Reports, as of 14 Jun 2017)

4 Impact

4.4 Cited Journal Data

Impact Factor	Citing Journal	Cited year	
		All years	2014-2015
1.572	BREAST CANCER	77	16
5.168	ONCOTARGET	29	9
3.522	EJSO-EUR J SURG ONC	24	4
3.626	BREAST CANCER RES TR	23	7
3.288	BMC CANCER	23	11
1.653	ONCOTARGETS THER	23	6
2.806	PLOS ONE	22	5
4.041	ANN SURG ONCOL	20	3
1.390	ONCOL LETT	20	6
4.259	SCI REP-UK	15	3
3.967	EUR RADIOL	12	1
3.650	TUMOR BIOL	11	4
1.937	ANTICANCER RES	11	1
1.803	MEDICINE	11	5
1.706	INT J CLIN EXP PATHO	11	2
3.362	CANCER MED-US	10	3
2.687	J CLIN PATHOL	10	3

Impact Factor	Citing Journal	Cited year	
		All years	2014-2015
2.297	BREAST J	10	2
2.801	BREAST	9	4
1.745	SURG TODAY	9	2
2.494	ULTRASOUND MED BIOL	8	2
24.008	J CLIN ONCOL	7	1
3.523	HISTOPATHOLOGY	7	1
3.226	INT J MOL SCI	7	1
2.816	CLIN BREAST CANCER	7	1
2.698	SUPPORT CARE CANCER	7	1
1.600	WORLD J SURG ONCOL	7	1
6.345	BREAST CANCER RES	6	2
2.735	STRAHLENTHER ONKOL	6	0
2.400	AM J CLIN PATHOL	6	3
2.204	J BREAST CANCER	6	1
1.130	SPRINGERPLUS	6	0
1.069	INT J CLIN EXP MED	6	2
ALL Journals		1,203	294

4 Impact

4.5 Highly Cited Articles Published in *Breast Cancer* (2014-2015), Cited in 2016

Title	Author	Article type	Year	Vol	Issue	Page	Citations
Functional significance of long non-coding RNAs in breast cancer	Rajeev Vikram	Review Article	2014	21	5	515	12
HER2-directed therapy: current treatment options for HER2-positive breast cancer	Shahid Ahmed	Review Article	2015	22	2	101	12
Prognostic significance of NANOG and KLF4 for breast cancer	Takuya Nagata	Original Article	2014	21	1	96	10
Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors	Yingchun Zeng	Review Article	2014	21	3	262	9
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer	Tatsuya Yoshioka	Original Article	2015	22	2	185	8
Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response	Patricio Godoy	Original Article	2014	21	4	491	7
Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer	Rie Horii	Original Article	2014	21	5	598	7
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011	Junichi Kurebayashi	Special Article	2015	22	3	235	7
Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial	Hulya Uzkeser	Original Article	2015	22	3	300	7

(Source: Clarivate Analytics, Web of Science, as of 14 Jun 2017)

4 Impact

4.5 — *continued* —

Title	Author	Article type	Year	Vol	Issue	Page	Citations
Photoacoustic mammography: initial clinical results	Toshiyuki Kitai	Original Article	2014	21	2	146	6
Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer	Eriko Tokunaga	Original Article	2014	21	3	341	6
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2	Shinzaburo Noguchi	Original Article	2014	21	6	703	6
Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells	Akira I. Hida	Original Article	2015	22	2	129	6
Thioglucose-bound gold nanoparticles increase the radiosensitivity of a triple-negative breast cancer cell line (MDA-MB-231)	Cuihong Wang	Original Article	2015	22	4	413	6
Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells	Chin-Ho Kuo	Original Article	2014	21	3	358	5
A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer	Fatemeh Bahreini	Original Article	2015	22	6	615	5

4 Impact

4.6 Highly Cited Articles Published in *Breast Cancer* (2011-2015), Cited in 2016

Title	Author	Article type	Year	Vol	Issue	Page	Citations
Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome	Masako Yamashita	Original Article	2012	19	2	170	16
The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis	Takeshi Imamura	Special Feature	2012	19	2	118	12
Functional significance of long non-coding RNAs in breast cancer	Rajeev Vikram	Review Article	2014	21	5	515	12
HER2-directed therapy: current treatment options for HER2-positive breast cancer	Shahid Ahmed	Review Article	2015	22	2	101	12
Prognostic significance of NANOG and KLF4 for breast cancer	Takuya Nagata	Original Article	2014	21	1	96	10
Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors	Yingchun Zeng	Review Article	2014	21	3	262	9
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer	Tatsuya Yoshioka	Original Article	2015	22	2	185	8
Reproductive history and breast cancer risk	Shunzo Kobayashi	Review Article	2012	19	4	302	7
Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response	Patricio Godoy	Original Article	2014	21	4	491	7
Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer	Rie Horii	Original Article	2014	21	5	598	7

(Source: Clarivate Analytics, Web of Science, as of 14 Jun 2017)

4 Impact

4.6 — *continued* —

Title	Author	Article type	Year	Vol	Issue	Page	Citations
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011	Junichi Kurebayashi	Special Article	2015	22	3	235	7
Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial	Hulya Uzkeser	Original Article	2015	22	3	300	7
Improvement of survival and prospect of cure in patients with metastatic breast cancer	Yee Chung Cheng	Special Feature	2012	19	3	191	6
Is MRI useful for the prediction of nipple involvement?	Naomi Sakamoto	Original Article	2013	20	4	316	6
Photoacoustic mammography: initial clinical results	Toshiyuki Kitai	Original Article	2014	21	2	146	6
Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer	Eriko Tokunaga	Original Article	2014	21	3	341	6
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2	Shinzaburo Noguchi	Original Article	2014	21	6	703	6
Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells	Akira I. Hida	Original Article	2015	22	2	129	6
Thioglucose-bound gold nanoparticles increase the radiosensitivity of a triple-negative breast cancer cell line (MDA-MB-231)	Cuihong Wang	Original Article	2015	22	4	413	6

4 Impact

4.7 The Status of Competing Journals

Rank	Journal title	Impact Factor 2016	Impact Factor without journal self cites	5-Year Impact Factor	Citable items	Total Cites	IF2015	IF2014
3	Lancet Oncology	33.900	33.250	31.194	169	38,110	26.509	24.690
5	Journal of Clinical Oncology	24.008	23.087	19.311	478	149,617	20.982	18.443
27	Breast Cancer Research	6.345	6.131	6.468	123	10,541	5.211	5.490
68	Cancer Science	3.974	3.894	3.757	228	11,075	3.896	3.523
82	Breast Cancer Research and Treatment	3.626	3.415	4.069	332	18,721	4.085	3.940
118	Clinical Breast Cancer	2.816	2.728	2.768	88	1,788	3.082	2.107
119	Breast	2.801	2.661	2.833	153	3,749	2.740	2.381
144	Breast Journal	2.297	2.252	1.982	80	2,354	1.920	1.411
150	Journal of Breast Cancer	2.204	2.080	2.156	59	741	1.854	1.788
155	International Journal of Clinical Oncology	2.064	1.987	1.870	154	2,204	1.806	2.128
163	Japanese Journal of Clinical Oncology	1.905	1.784	1.931	167	4,321	1.889	2.016
183	Breast Cancer	1.572	1.487	1.561	113	1,203	1.182	1.585
184	Breast Care	1.553	1.495	1.383	55	543	1.645	0.627

(Source: Clarivate Analytics, Journal Citation Reports, as of 14 Jun 2017)